CAV3
CAV3 (caveolin 3, also known as VIP-21, VIP21, LGMD1C and LQT9) is a member of the caveolin family and a component of caveolae in the plasma membrane. It is proposed to act as a scaffolding protein within caveolar membranes, and it contributes to sarcolemma repair. Browse Assay Genie's current range of CAV3 research reagents below, or read on for the biology behind the target.
CAV3 may act as a scaffolding protein within caveolar membranes, where caveolin proteins are proposed to organise and concentrate certain caveolin-interacting molecules. It interacts directly with G protein alpha subunits and can functionally regulate their activity, and it may also regulate voltage-gated potassium channels. CAV3 also plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes, which permits rapid resealing of membranes disrupted by mechanical stress. In addition, it mediates the recruitment of CAVIN2 and CAVIN3 to the caveolae.
The CAV3 gene encodes a caveolin family member that is a component of the caveolae plasma membranes found in most cell types. UniProt records the protein at the cell membrane, in caveolae and the sarcolemma, and at the Golgi apparatus membrane. Alternative splicing has been identified at this locus, with inclusion or exclusion of a differentially spliced intron. Transcripts also use multiple polyA sites and contain two potential translation initiation sites. HGNC places the gene in the caveolins group, alongside CAV1 and CAV2, and mouse and rat each have a Cav3 ortholog.
Mutations in the CAV3 gene interfere with protein oligomerisation or intracellular routing, which disrupts caveolae formation. These changes result in Limb-Girdle muscular dystrophy type-1C (LGMD-1C), hyperCKemia or rippling muscle disease. The aliases LGMD1C and LQT9 reflect these disease associations, while VIP-21 is an older name for the protein.
CAV3 is a caveolin family component of caveolae and is proposed to organise and concentrate caveolin-interacting molecules in these membrane domains.
CAV3 contributes to sarcolemma repair in skeletal muscle and cardiomyocytes, allowing rapid resealing of membranes disrupted by mechanical stress.
CAV3 mutations disrupt caveolae formation and lead to LGMD-1C, hyperCKemia and rippling muscle disease, making it a focus in muscle disease studies.
CAV3 binds G protein alpha subunits and can regulate their activity, and it may also regulate voltage-gated potassium channels.
CAV3 may act as a scaffolding protein within caveolar membranes. It interacts directly with G protein alpha subunits, may regulate voltage-gated potassium channels, and takes part in sarcolemma repair in skeletal muscle and cardiomyocytes. It also recruits CAVIN2 and CAVIN3 to caveolae.
CAV3 is the HGNC symbol for caveolin 3, which UniProt lists as Caveolin-3. Aliases and previous symbols include VIP-21, VIP21, LGMD1C and LQT9. Alternative splicing has been reported at the locus, and transcripts contain two potential translation initiation sites.
Yes. CAV3 mutations disrupt oligomerisation or intracellular routing and impair caveolae formation, causing LGMD-1C, hyperCKemia or rippling muscle disease. Mouse and rat both have a Cav3 ortholog; check the datasheet of any product for its validated reactivity.
Other caveolins and caveolae-associated proteins with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P56539; product specifications from Assay Genie datasheets.